Target intelligence / Profile preview

Non-structural protein 1 (NSP1) (NSP1)

Target
NSP1
Molecular classification
Viral non-structural protein, E3 ubiquitin ligase, RNA-binding protein, Metalloprotein
01

Overview

Rotavirus nonstructural protein 1 (NSP1) is a critical virulence factor encoded by gene segment 5 that functions as a powerful antagonist of the host innate immune response. It primarily acts by hijacking host cellular machinery, specifically Cullin-RING ligases (CRLs), to induce the proteasomal degradation of key transcription factors such as interferon regulatory factors (IRF3, IRF5, IRF7, and IRF9) [1, 10, 13]. Additionally, in many human and porcine strains, NSP1 targets the β-transducin repeat-containing protein (β-TrCP) for degradation, thereby preventing NF-κB activation and further suppressing the production of type I and III interferons [14, 15]. Beyond interferon antagonism, NSP1 interacts with host proteins like p53 to suppress early-stage apoptosis and can degrade RNase L to subvert the OAS-RNase L antiviral pathway [11, 12]. Although NSP1 is not always essential for viral replication in vitro, its role in suppressing the host immune response makes it vital for viral spread and pathogenesis in vivo [15, 16]. Consequently, NSP1 is a significant target for the development of novel antiviral strategies and the engineering of live-attenuated vaccines. Research into inhibitors that block NSP1's ability to recruit host ligases, such as neddylation inhibitors, highlights its potential as a therapeutic target [2].

Other names
NCVP2NS53Non-structural RNA-binding protein 53Gene 5 productRotavirus nonstructural protein 1
02

Mechanism of action

Induces proteasomal degradation of host antiviral proteins by hijacking host Cullin-RING ubiquitin ligases (CRL1 and CRL3) to act as a viral E3 ligase mimic, or inhibits targeting pathways through direct interaction with signaling proteins such as RIG-I and p53 [6, 11, 13].

03

Biological functions

Immune responseApoptosisSignal transductionInterferon antagonismHost innate immunity inhibition
04

Disease associations

InfectionGastroenteritis
05

Safety considerations

High sequence diversity between rotavirus strains complicates broad-spectrum drug development [8, 13].Strain-specific targeting of different host proteins (e.g., IRF3 vs. β-TrCP) [5, 14].Potential for rapid viral evolution and emergence of resistance under therapeutic pressure [7, 13].
06

Interacting drugs

MLN4924 (Pevonedistat)

1 more in the full profile.

07

Biomarkers

Fecal viral sheddingRotavirus-specific serum IgARotavirus-specific serum IgGInterferon-beta (IFN-β) levels (experimental)IRF3 protein levels (experimental)

Beyond the preview

Go deeper on Non-structural protein 1 (NSP1) (NSP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-structural protein 1 (NSP1) (NSP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call